ProQR Therapeutics N.V. (PRQR)
Company Description
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; AX-9115 for rare metabolic condition; and AX-2402 for rare neurodegenerative conditions, as well as other targets in its discovery pipeline.
In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 2012 |
| IPO Date | Sep 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Daniel Anton de Boer |
Contact Details
Address: Zernikedreef 9 Leiden, P7 2333 CK Netherlands | |
| Phone | 31 88 166 7000 |
| Website | proqr.com |
Stock Details
| Ticker Symbol | PRQR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612940 |
| CUSIP Number | N71542109 |
| ISIN Number | NL0010872495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Domenico Valerio Ph.D. | Founder and Independent Chairman of Supervisory Board |
| Daniel Anton de Boer | Founder, Chief Executive Officer and Member of Management Board |
| Dr. Gerard Platenburg | Co-Founder and Chief Scientific Officer |
| Jurriaan Dekkers | Chief Financial Officer |
| Rene K. Beukema | Chief Corporate Development Officer, General Counsel and Member of Management Board |
| Sheila Sponselee | Vice President and Head of People and Operations |
| Sarah Cue Kiely | Vice President of Investor Relations and Corporate Communications |
| Bart Klein | Senior Vice President of Intellectual Property |
| Aniz Girach M.D. | Chief Medical Officer |
| Sandra van der Kolk | Jr. Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 27, 2023 | 6-K | Report of foreign issuer |
| Sep 14, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 3, 2023 | 6-K | Report of foreign issuer |
| Aug 1, 2023 | 6-K | Report of foreign issuer |
| May 17, 2023 | 6-K | Report of foreign issuer |
| May 16, 2023 | 6-K | Report of foreign issuer |
| Apr 24, 2023 | EFFECT | Notice of Effectiveness |
| Apr 24, 2023 | 424B5 | Filing |
| Apr 18, 2023 | 6-K | Report of foreign issuer |
| Mar 29, 2023 | RW | Filing |